Molecular biology and molecular diagnosis in parasitology
- General parasitology
What PCR, genotyping and resistance markers add to the microscope in parasitology, and when they do not help the patient in front of you.
What it is
Molecular methods detect parasite DNA or RNA, tell apart species that look identical under the microscope, follow outbreaks and track genes linked to drug resistance or to test failure. They complement microscopy and serology but do not replace them: in acute malaria, for example, a smear or rapid test gives the answer in time, and PCR mostly confirms the species. Molecular surveillance mainly guides national programmes rather than single treatment decisions.
Key facts
- Artemisinin partial resistance means slower parasite clearance after artemisinin-based combinations; it rarely causes treatment failure unless the partner drug also fails.
- WHO keeps a list of validated PfKelch13 mutations used to map artemisinin partial resistance.
- Parasites lacking HRP2/HRP3 have been reported in many countries, with high prevalence in parts of South America such as Peru and Brazil.
- Molecular markers guide national treatment policy alongside repeated therapeutic efficacy studies.
Molecular tools and what they answer
| Tool | Question it answers | Examples |
|---|---|---|
| Species-specific PCR | Which species is this? | Entamoeba histolytica versus the harmless, identical-looking E. dispar; confirming Plasmodium species |
| Real-time (quantitative) PCR | Is it there at very low levels, and how much? | Low-density malaria; Strongyloides in stool |
| Isothermal amplification (LAMP) | Can we test without a thermocycler? | Strongyloides and malaria in less equipped laboratories |
| Genotyping and sequencing | Which strain, and are cases linked? | Leishmania species identification; Cryptosporidium species and subtypes in outbreaks |
| Drug-resistance markers | Is resistance appearing in this region? | PfKelch13 mutations with artemisinin partial resistance; pfcrt with chloroquine resistance in P. falciparum |
| Gene-deletion surveillance | Will our rapid test miss infections? | P. falciparum lacking HRP2 and HRP3 escapes HRP2-based rapid tests |
| Antigen discovery | What can a vaccine target? | The circumsporozoite protein in the RTS,S and R21 malaria vaccines |
Clinical notes
- A stool report of 'E. histolytica/E. dispar' cannot be called amoebiasis on microscopy alone; molecular tests or antigen tests separate them.
- In a feverish traveller, malaria microscopy or a rapid test comes first; waiting for PCR delays treatment.
- Species of Leishmania predict the risk of mucosal disease and can guide the choice of drug.
In the lab
- Blood for malaria PCR goes in an anticoagulant tube; stool for PCR is sent fresh, frozen or in a preservative that does not damage DNA (not formalin).
- PCR detects DNA, not viability: it may stay positive briefly after effective treatment.
- Results need controls against contamination and an expert who interprets them with the clinical picture.
- For African trypanosomiasis no nucleic acid test is yet validated for diagnosis; microscopy and serology lead.
Common traps
- A positive PCR after treatment means treatment failed: PCR detects DNA, not living parasites, and can stay positive briefly after effective treatment.
- Quadrinucleate Entamoeba cysts in stool mean amoebiasis: E. histolytica and the harmless E. dispar look identical, and only molecular or specific antigen tests separate them.
- Waiting for malaria PCR is the safest way to confirm the diagnosis: in an acutely ill patient a smear or rapid test guides immediate treatment, and PCR comes too late.
- A negative HRP2 rapid test rules out P. falciparum: parasites with HRP2/HRP3 deletions escape it, a problem reported in parts of South America.
- Artemisinin partial resistance means the combination no longer works: it slows parasite clearance and rarely causes failure unless the partner drug also fails.
Test yourself
Think of the answer, then tap the question to see it.
A febrile traveller from the Amazon has a negative HRP2-based rapid test but a smear showing P. falciparum. How can both be true?
Parasites lacking the HRP2/HRP3 genes make no target antigen for the test; microscopy still sees them.
A stool sample sent in formalin is rejected for Strongyloides PCR. Why?
Formalin damages DNA; stool for PCR is sent fresh, frozen or in a preservative that keeps DNA intact.
Why does identifying the Leishmania species matter for a patient with a skin ulcer?
The species predicts the risk of later mucosal disease and can guide the choice of drug.
A national programme finds validated PfKelch13 mutations in local P. falciparum. What does that change?
It signals artemisinin partial resistance, so the programme checks treatment efficacy and the partner drug and may revise national policy; it is surveillance, not a test for one patient.
A febrile patient may have malaria and PCR takes two days. What guides treatment today?
A blood smear or rapid test, acted on at once; PCR, if sent, only confirms the species later.
Connections
Microorganisms11
- Plasmodium falciparum
- Plasmodium vivax
- Entamoeba histolytica
- Commensal intestinal amoebae (Entamoeba coli, E. dispar, Endolimax nana and others)
- Strongyloides stercoralis
- Leishmania (Viannia) panamensis, L. braziliensis and L. guyanensis
- Leishmania infantum
- Cryptosporidium spp.
- Trypanosoma brucei gambiense and T. b. rhodesiense
- Trypanosoma cruzi
- Trypanosoma rangeli
In Pharmacology3
Educational content on microorganisms; not a treatment guide and no substitute for a health professional's advice. No doses are given.
Sources: Malaria Diagnostic Tests | Malaria | CDC (CDC, 2024); Malaria: Artemisinin partial resistance (World Health Organization, 2025); Malaria (World Health Organization, 2025); CDC - DPDx - Amebiasis (CDC DPDx, 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
